@article{158d6a172faa437298deb24a406a92f7,
title = "Association Between Insomnia and Asthma Burden in the Severe Asthma Research Program (SARP) III",
abstract = "Background Sleep difficulties are commonly reported by patients with asthma; however, the prevalence of insomnia and its association with disease burden and well-being is unknown. We aimed to determine the prevalence of insomnia, defined as combined sleep-specific complaints with associated daytime symptoms, among a large sample of adults with asthma, and to compare well-being, asthma control, and asthma-related health care utilization in individuals with asthma and insomnia and those without insomnia. Methods Baseline data from adults with physician-confirmed asthma enrolled in the Severe Asthma Research Program III was used for analyses (N = 714). Participants completed the Insomnia Severity Index (ISI), Asthma Control Test, Asthma Quality of Life Questionnaire, and Hospital Anxiety and Depression Scale. Results Insomnia (ISI ≥ 10) was identified in 263 participants (37%). Presence of insomnia was associated with higher levels of depression and anxiety symptoms and poorer quality of life. Those with insomnia had a 2.4-fold increased risk for having not well-controlled asthma and a 1.5-fold increased risk for asthma-related health care utilization in the past year compared with those without insomnia. Conclusions Insomnia is highly prevalent in asthma and is associated with adverse outcomes. Further studies are needed to gain a better understanding of the interaction between insomnia and asthma control.",
keywords = "asthma, depression, health care utilization, insomnia, quality of life",
author = "Luyster, {Faith S.} and Strollo, {Patrick J.} and Fernando Holguin and Mario Castro and Dunican, {Eleanor M.} and John Fahy and Benjamin Gaston and Elliot Israel and Jarjour, {Nizar N.} and Mauger, {David T.} and Moore, {Wendy C.} and Wenzel, {Sally E.}",
note = "Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: P. J. S. has received personal fees from ResMed, Inspire Medical Systems, and Philips Respironics; been a board member for the National Football League Cardiovascular Health Committee; and given expert testimony for Harris v Emory. M. C. has received grant funding from Boehringer Ingelheim, Amgen, Teva, Novartis, GlaxoSmithKline, sanofi-aventis, Vectura, MedImmune, Johnson & Johnson, Invion, Pfizer, and KaloBios; received personal fees from GlaxoSmithKline, Genentech, Boston Scientific, Boehringer Ingelheim, Elsevier, NeoStem, Teva, and Holaira; and held stock in Sparo. J. F. has received consultant fees and grants from Boehringer Ingelheim, Dynavax, Genentech, Pfizer, Medimmune, and Theravance. E. I. has received personal fees from AstraZeneca, Novartis, Cown & Co., Teva, Philips Respironics, Regeneron, and UpToDate; received grant funding from Genentech; given expert testimony for Campbell, Campbell, Edwards & Conroy, Crammer, Bishop, & O{\textquoteright}Brien, Fox Rothschild, and Ryan Ryan Deluca; been a member of the data and safety monitoring board for Novartis; and received travel expenses from Research In Real Life and Teva. N. N. J. has received grant funding from Teva, AstraZeneca, and Diichi Sankyo. None declared (F. S. L, F. D., E. M. D., B. G., D. T. M., W. C. M., S. E. W.). Funding Information: FUNDING/SUPPORT: This study was funded by the National Institutes of Health [NIH U10HL 109164, U10HL 109257, U10HL 109250, U10HL 109172, U10HL 109168, U10HL 109152, U10HL 109046, U10HL 109046]. Support for the first author was provided by the National Heart, Lung, and Blood Institute (NHLBI) K23 HL105887. Publisher Copyright: {\textcopyright} 2016 American College of Chest Physicians",
year = "2016",
month = dec,
day = "1",
doi = "10.1016/j.chest.2016.09.020",
language = "English",
volume = "150",
pages = "1242--1250",
journal = "Chest",
issn = "0012-3692",
number = "6",
}